Phase 4 EpiCom Study Highlights Potential of CBD in Neuropsychiatric Disorders of Tuberous Sclerosis Complex

Published Date: 08 Dec 2024

CBD maintained a favorable safety profile, with 63% of participants experiencing adverse events such as diarrhea, vomiting, decreased appetite, and lethargy, leading to discontinuation in four patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot